SEC Form 4 · accession 0000899243-17-027954
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samarth Kulkarni
Officer — Chief Executive Officer
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | Dec 1, 2017 | A | 26,667 | $19.12 | A | 133,560 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.12 | Dec 1, 2017 | A | 260,000 | A | — | Dec 1, 2027 | Common Shares | 260,000 | 260,000 | D |
Explanation of responses
- F1This option was granted on December 1, 2017 and shall vest in 48 equal monthly installments.